R
heumatoid arthritis (RA) is a chronic disease characterized by systemic inflammation that leads to joint damage and disability and may be associated with increased risk of cardiovascular disease (CVD), a major cause of morbidity and mortality in RA. 1 The relationship between RA disease activity, lipid levels, and CVDs is complex. 2, 3 However, CVD risk factor modification, such as reducing total cholesterol (TC) and plasma glucose, may be beneficial for preventing CVD. Hydroxychloroquine (HCQ), a disease-modifying antirheumatic drug (DMARD) with a good safety profile and low cost, has been reported to improve lipid profiles [4] [5] [6] and glucose level in RA. 7, 8 We aimed to examine the association between the use of HCQ and plasma lipid and glucose levels in a large RA cohort.
PATIENTS AND METHODS
From 1996 to 2009, we recruited 1328 consecutive patients who met the 1987 criteria for RA 9 from private and public rheumatology clinics in San Antonio, TX. We have described this cohort in previous publications. [10] [11] [12] All patients participated in a comprehensive baseline evaluation of their clinical and psychosocial characteristics conducted by a physician and trained research assistants. We followed patients prospectively for yearly follow-up evaluations in which we assessed clinical features of RA, laboratory measures, and DMARD use. The study protocol was approved by our institutional review board, and all patients provided signed, informed consent.
Variables
Demographic information included age, sex, ethnicity, and duration of RA. The duration of RA was considered to be the time between RA diagnosis and the evaluation date. For clinical purpose, we include prednisone use; tender, swollen, and deformed joint counts; Disease Activity Score (DAS28 ESR); and hand Sharp score.
13,14

Laboratory Studies
The erythrocyte sedimentation rate (ESR) was measured by the Westergren technique. Total plasma cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL), and glucose were measured using a Synchron LX automated system (Beckman Coulter, Fullerton, CA). Patients were asked to fast overnight before laboratory testing.
Statistical Analysis
We performed cross-sectional analyses comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ at baseline. We subsequently divided patients into 3 groups based on HCQ exposure: those who did not take HCQ during the time of our study, those who took it intermittently, and those who took it continuously throughout the study. Using these groups, we performed generalized estimated equation (GEE) regression models including all follow-up visits to examine plasma lipid and glucose levels by HCQ exposure. We adjusted for age, sex, duration of RA, ethnicity, and use of lipid-lowering medications, anti-tumor necrosis factor α medications, and other nonbiologic DMARDs including methotrexate, sulfasalazine, leflunomide, azathioprine, and diabetes medication. We also compare visits with and without HCQ, using the GEE regression model. In an alternative approach to account for potential confounding by indication, we estimated the patient's propensity to receive HCQ and use the propensity score as a covariate in regression model. The propensity score was the predicted probability that a patient would be taking HCQ at a given visit, which was calculated from a logistic regression model using the independent variables listed in Tables 1 to 3 .
RESULTS
A total of 1328 patients were recruited into the study. However, 67 lacked complete lipid profiles, so our final sample included 1261 patients (938 female and 323 male patients) with a mean age of 59.6 (SD, 11.5)years. At baseline, 254 patients were on HCQ, and 1007 patients were not. After adjusting for age, sex, ethnicity, lipid-lowering medications, body mass index (BMI), smoking, and use of any other DMARDs, patients taking HCQ had significantly lower TC (P ≤ 0.001), LDL (P < 0.001), triglycerides (TGs) (P = 0.009), and lipid profile ratios TC/HDL (P < 0.001) and LDL/HDL (P < 0.001) compared with those who were not taking HCQ. Furthermore, HDL was significantly higher in patients taking HCQ (P < 0.001). Plasma glucose level was not significantly associated with HCQ use (P = 0.2). Patients taking HCQ at baseline also had significantly lower ESR (P = 0.042), although this association lost statistical significance after the adjustment of other DMARD use (P = 0.1).
With respect to clinical analysis including prednisone use, swollen and tender joints, DAS28 ESR, and Sharp score, there were no statistically significant differences between those who were currently taking HCQ versus those who were not, except for DAS28 ESR and any other DMARD (Table 1) .
When taking into account follow-up visits, we divided patients based on HCQ exposure: those who had never taken HCQ during the time of our study (used as referent group), those who took it intermittently, and those who took it continuously throughout their time in the study. After adjusting for confounders, the patients who had never taken HCQ had significantly higher TC (P = 0.03, P = 0.01), LDL (P = 0.03, P < 0.001), TG (P < 0.01, P < 0.01), and lipid profile ratios TC/HDL (P = 0.001, P < 0.001) and LDL/HDL (P = 0.04, P < 0.001) when compared with those who took the drug intermittently or continuously, respectively. High-density lipoprotein was significantly higher in patients who took HCQ continuously versus those who have never taken it (P < 0.001). Hydroxychloroquine use was associated with lower plasma glucose concentration, but the difference was not significant after adjusting for the propensity score (Table 2) . Patients who had never taken HCQ had significantly higher ESR compared with those who took it continuously throughout the study (P = 0.04), although there was no significant difference when compared with those who took the drug intermittently (Table 2) . In all models, compared with patients with no HCQ exposure, patients taking HCQ continuously showed a more significant improvement in lipid profiles, glucose, and ESR than did those who took it intermittently.
We found the following average differences in lipids comparing the never-exposed versus continuously-exposed groups in the pooled follow-up visits: LDL decrease of 9.3 mg/dL (P < 0.001), TG decrease 16.8 mg/dL (P < 0.001), TC decrease 4.7 mg/dL (P < 0.01), HDL increase 7.8 mg/dL (P < 0.001), LDL/HDL decrease 0.45 (P < 0.001), and TC/HDL decrease 0.59 (P < 0.001).
When we compare follow-up visits of patients with and without HCQ treatment, we found also statistically significant differences in all lipids levels (P < 0.0001) ( Table 3) . We were unable to obtain articular data at all visits on 147 patients; of these, 116 patients were never exposed to HCQ, 24 were intermittently exposed, and 7 patients were continuously taking HCQ. We were unable to obtain both articular data and ESR at all visits on 177 patients; of these, 134 patients were never exposed to HCQ, 33 were intermittently exposed, and 10 patients were continuously taking HCQ. d We were unable to obtain hand radiographs at all visits on 987 patients; of these, 670 patients were never exposed to HCQ, 273 were intermittently exposed, and 44 patients were continuously taking HCQ.
With respect to clinical findings, swollen joints, DAS28 ESR, and Sharp score were less severe in the group of patients who continuously took HCQ versus those who never took HCQ (P < 0.01), and deformed joints and Sharp score were also significantly different in the group who intermittently took HCQ compared with those who had never taken it (P ≤ 0.01) ( Table 2) .
We tested an HCQ Â ethnic group interaction in the models for lipid measurements, and it was not significant. This finding suggests that the effect of HCQ does not vary between ethnic groups.
DISCUSSION
Despite recent advances in medical treatment, high cholesterol remains a significant public health problem in the United States, with more than a quarter of adults aged 40 to 74 years having high LDL cholesterol. 15 Increased risk in CVD morbidity and mortality has been described in RA patients, independent of traditional risk factor such as hypertension, diabetes, hyperlipidemia, smoking, or increased age. 16, 17 Our results suggest that HCQ is associated with significantly lower TC, TG, and LDL, as well as a significant increase in HDL, in RA patients. These findings are particularly important because RA patients are predisposed to CVD.
In 1997, a prospective randomized clinical trial comparing the effect of intramuscular gold and HCQ on lipid profiles of RA patients suggested that HCQ has beneficial effects on lipids. Patients in the HCQ group had significantly higher HDL and lower TC compared with the intramuscular gold group. In a cohort of 706 RA patients, Morris et al 4 demonstrated that use of HCQ was associated with a significant decrease in LDL of 7.55 mg/dL, decrease in TC of 7.70 mg/dL, decrease in LDL/HDL of 0.136, and decrease in TC/HDL of 0.191, with a nonsignificant increase of 1.02 mg/dL in HDL. Similarly, we found significantly lower average LDL, TG, TC, LDL/HDL, and TC/HDL, as well as a significant increase in HDL, in patients taking HCQ. However, the average differences were greater than or similar to those in our cohort with respect to LDL, LDL/HDL, TG, and TC/HDL. The significant increase in HDL is important to note because HDL is considered a powerful predictive tool, independent of other known coronary heart disease risk factors among postmenopausal women. 18 In another study of 155 women with RA or systemic lupus erythematosus (SLE), an association was found between HCQ treatment and low serum level of TC, LDL, and TG level, but with no increased level of HDL. 6 In a more recent and smaller study of 72 patients with lupus followed up for 2 years, levels of TC, TG, LDL, and HDL were significantly improved after treatment with HCQ. 19 Similar findings, showing the benefit of HCQ as a lipidlowering medication, have been shown in SLE patients. 6, 15, [19] [20] [21] [22] In a cross-sectional study, Tam et al 23 studied 123 patients with lupus and found that TC, very low-density lipoprotein, and LDL levels were significantly lower in patients taking antimalarial including patients taking concomitant prednisone. The cholesterollowering effect of HCQ was found more pronounced in those SLE patients who are in stable doses of steroid or those who are initiating treatment with steroids. 24 However, in our cohort, we did not find any differences when comparing HCQ in patients taking or not taking corticosteroids, probably because prednisone use was similar in patients taking HCQ and those who were not taking it.
Considering that patients with RA have more difficulty in achieving a goal LDL when treated with statins compared with the general population, 25 HCQ is a reasonable and inexpensive adjuvant alternative to control the high TC or LDL level. Although the absolute differences in lipid levels are not great, the statistical significance is high. Considering that small decrease in lipids level may be a protective factor in major CVD, especially in secondary prevention, the differences that we found may still have clinical relevance.
The exact mechanism by which HCQ can lower plasma lipid levels is still unknown. It has been reported that chloroquine, which is related to HCQ, is a potent inhibitor of cholesterol biosynthesis by isolated rat hepatocytes 26 and may increase LDL receptors, activity of HMG-Co reductase, and slow degradation of this enzyme. 27 The beneficial effect on glucose metabolism may also play an important role in decreasing lipid level. 28 In addition to lowering cholesterol, HCQ may improve plasma glucose levels. Insulin resistance is highly prevalent in RA patients, and this condition may play an important role in subclinical atherosclerosis. 29 Although not all studies confirm that HCQ improves the sensitivity to insulin, 30 others have shown improvement in insulin sensitivity and a decrease in TC and TG level. 31 The glucose-lowering efficacy, responsiveness, duration of action, and impact on quality of life of HCQ, when added as an antihyperglycemic agent to patients with sulfonylurea-refractory type 2 diabetes, were demonstrated in a study with 135 obese patients with type 2 diabetes, especially in those with glycosylated hemoglobin less than 13.5%. 32 In our study, we found no difference in the plasma glucose level at baseline, and the difference during the follow-up visits was not significant after adjusting for confounding.
Our study addressing HCQ as a lipid-lowering medication in RA patients has strengths and limitations. Among its strengths, our cohort is large enough to provide the power to detect small effects. It is a prospective observational study in which a rheumatologist examined the patients, systematically asking questions about any medications that they were taking and drawing blood for complete metabolic profile during each visit. We also have the benefit of a diverse cohort, recruited from a variety of health systems and socioeconomic strata. Furthermore, compared with patients taking HCQ, those who were not had similar ESR and DAS28 ESR at baseline, thus decreasing the likelihood of an indication bias. We also used these data to score the patient's propensity to be receiving HCQ at each visit. These propensity scores, which were used as covariates in multivariable models, compensate for the effect of nonrandom treatment assignment. 33 The association of HCQ with lower lipid profile remained significant after adjustment for propensity score. One possible limitation is the fact that the recruitment period was quite long (1996-2009) during which there may have been changes in the management of patients, beyond pharmacologically, but also in the delivery of service. There may have been changes in health care policy, which may have affected the outcomes we measured. Moreover, the pattern of use of HCQ regimen could have also changed over time.
CONCLUSIONS
Hydroxychloroquine use was associated with significantly lower TC, LDL, TG, and TC/HDL and LDL/HDL ratios and with higher HDL. The association of HCQ with plasma glucose was not statistically significant after adjusting for confounding. Minimizing risk of CVD in RA patients remains a major concern in treating these patients. These findings suggest HCQ may help in reducing some traditional CV risk factors. Large randomized trials are needed to establish the potential of HCQ in CVD prevention in RA patients.
